TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter phase 2 study evaluating the efficacy and safety of
trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not
amenable to curative treatment by surgery or radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Borstkanker Onderzoek Groep
Collaborators:
BOOG Study Center Erasmus Medical Center Servier UMC Utrecht